Polaris Venture Partners is a partnership of experienced venture capital investors and technology executives. Our mission is to identify and invest in seed, first round, and early stage technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies. In addition, Polaris is committed to providing growth equity and shareholder liquidity to established companies in the technology, healthcare, manufacturing, media, communications, and business services sectors. As a national venture capital firm with offices in the high-tech centers of Boston and Seattle, we’re able to invest in businesses throughout the United States and around the world. The firm has over $3 billion under management and current investments in more than 100 companies.

Through our philosophy of lead investing and active, long-term partnering with early stage and growing revenue stage companies, the firm has helped a number of companies achieve outstanding success. Among them are Advanced Inhalation Research (AIR) (sold to Alkermes); Akamai Technologies, Inc. (NASDAQ: AKAM); Allaire Corporation (sold to Macromedia); Aspect Medical Systems (NASDAQ: ASPM); Centra Software (NASDAQ: CTRA); deCODE genetics (NASDAQ: DCGN); Paradigm Genetics, Inc. (NASDAQ: PDGM); and Solidworks (sold to Dassault Systemes).